Mylan’s Eplerenone Among Seven US Divestments For Viatris
But FTC-Directed Product Divestitures Come Under Fire
Mylan and Pfizer’s Upjohn must make a total of seven product divestments to close on their proposed combination to Viatris, while conditions were placed on a further three products. The FTC’s means of remedying competition concerns via product divestitures has once again come under fire.
You may also be interested in...
Endo’s Par looks set to provide much needed supply in the US market for varenicline tablets, after originator Pfizer ran into supply and distribution problems due to the presence of a nitrosamine for its Chantix original.
Nearly 16 months after it was first announced, the $12bn merger of Mylan and Pfizer’s Upjohn has completed, with the resulting company Viatris preparing to unveil restructuring plans by the end of 2020.
Presenting its last ever financial earnings as a standalone company, Mylan revealed plans to host an Investor Day in the first quarter of next year to discuss the strategic direction of Viatris, Mylan’s proposed combination with Pfizer’s Upjohn which is due to close later this month.